La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aluf Hldgs a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aluf Hldgs..

Aluf Hldgs (OTC:AHIX) Azioni, Catena delle Opzioni

Aluf Holdings Inc is a holding company engaged in acquiring, operating, and managing subsidiary companies in the development and sale of software. It focuses on acquiring businesses with a business plan in the software and technology sectors. The company develops and manages software, technology, and cyber security companies as subsidiaries, through strategic acquisitions. Geographically, operations are functioned in the United States.

Aluf Holdings Inc

Earnings

News

Guidance

SUPV

Grupo Supervielle Q3 Net Income AR$8.9B; Confirm 15% ROE Guidance For FY2024

The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease (MRD) test for early-stage colorectal cancer (CRC) – in favor of Signatera&#x2122;, Natera's competing product.&nbsp;

Legal

NTRA

Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages

CHCI

Comstock Holding Says Carr Workplaces Signed New 26,331 Square Foot Lease At The Hartford In Arlington, Virginia

Shares of Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) traded higher on Monday in response to President-elect Donald Trump&#8217;s plans to nominate Marty Makary to lead the Food and Drug Administration (FDA). Here&#8217;s <a href="https://www.benzinga.com/quote/HIMS/news">what you need to know.</a>
What To Know: Market optimism surrounding Makary's selection may have bolstered Hims &amp; Hers shares on Monday as investors anticipate that the nomination could bring favorable regulatory changes to the sector. Makary is a proponent of telehealth and an executive at Sesame, a company that connects consumers to physicians who can prescribe compounded weight-loss drugs.
Hunterbrook Capital released a <a href="https://hntrbrk.com/hims-follow-up/">bullish report</a> on Monday announcing a long position in Hims &amp; Hers Health, citing potential benefits from Makary&#8217;s leadership at the FDA. The report suggests that Makary's background and expertise could stabilize the compounded GLP-1 drug market, in which Hims &amp; Hers Health is actively involved.
The report also highlighted regulatory challenges Hims &amp; Hers Health has faced, including fluctuating FDA guidance on <a href="https://www.benzinga.com/news/earnings/24/11/41718402/whats-going-on-with-hims-hers-health-stock-monday">drug shortages</a> and scrutiny over its prescribing practices. Makary's history with telehealth and compounded drugs may signal a more supportive regulatory environment, driving investor optimism.
Hims has been expanding into the weight-loss drug market with compounded GLP-1 products, which are cheaper alternatives to branded drugs like Wegovy and Mounjaro. Regulatory clarity under Makary's potential leadership is seen as a positive development for the company.
HIMS Price Action: Hims &amp; Hers shares closed Monday up 23.9% at $31.39, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png" alt="" class="wp-image-664105" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1.png 1468w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/24/11/42172722/gold-down-over-3-rigetti-computing-shares-spike-higher">Gold Down Over 3%; Rigetti Computing Shares Spike Higher</a></li>
</ul>
Image: Mohamed Hassan from Pixabay

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

What's Going On With Hims & Hers Health Stock Monday?

HSAI

Hesai Group Expects Q4 Net Revenues To Approach $100M

Agora Expects Q4 Total Revenues To Be $34M - $36M, Also Expects Significant Improvement In Net Income / (Loss)

Hesai Q3 Adj EPS $(0.05) Misses $(0.02) Estimate, Sales $76.87M Beat $69.82M Estimate

For NBC, big balloons mean a bigger budget.
What Happened: The Macy's Thanksgiving Day Parade, known for its extravagant performances and cartoon character floats, is getting pricier. 
Since 1953, the peacock-branded network has aired the iconic turkey-day tradition. And, according to <a href="https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=hp_lead_pos5">The Wall Street Journal</a>, NBC is considering a $60-million agreement — triple the current $20 million rate — to secure those rights through the next decade. 
See Also: <a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a>
So why the hefty price? Consider the appeal of live events in a streaming-dominated world. 
Comcast Corp.-owned (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) NBC and other traditional forms of TV are struggling to keep audiences after the whole cord-cutting trend. Marquee moments like parades, football games, boxing matches and awards shows are now popping up streaming services.
For NBC, the bet is that Peacock streaming customers will tune into the Nov. 28 crowd-pleaser, which is expected to feature celebrity appearances and live Broadway performances. 
Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) can relate. The Burbank, California-based conglomerate shelled out a 20% premium to swipe the Grammy Awards from Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), which had been airing it on CBS.
Why It Matters: The value of a live audience is as buoyant as a giant Snoopy balloon.
Nearly 30 million viewers tuned in to watch last year's parade, and this Thursday morning promises another spectacle of at least 11 marching bands, 28 clown crews, 22 balloons and 33 floats.
As for performers, viewers can expect a lineup of famous faces, including Charli D'Amelio, original &#8220;Wicked&#8221; star Idina Menzel, &#8220;Tonight Show&#8221; host Jimmy Fallon with The Roots, Coco Jones, Liza Colón-Zayas, The Temptations, T-Pain and the New York Liberty.
The route stretches 2.5 miles. It begins at 77th Street and Central Park West and winds its way down to Macy's Herald Square, the flagship store of Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>).
For those in New York City eager to preview the parade prep, the balloon inflation event happens Wednesday, Nov. 27, on the Upper West Side — a chance to get up close and personal with the towering inflatable icons.
Per <a href="https://www.usatoday.com/story/entertainment/tv/2024/11/21/macys-thanksgiving-day-parade-2024/76454992007/">USA Today</a>, this year&#8217;s event will debut new balloons, including Minnie Mouse, the Extraordinary Noorah and Gabby from Gabby&#8217;s Dollhouse.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment">Macy&#8217;s Delays Q3 Earnings Report Amid Investigation Over $154M Accounting Scandal; Stock Dips</a></li>
</ul>
Photo: Shutterstock

Entertainment

Events

Media

CMCSA

PARA

PARAA

Peacock Pays Up: Macy's Thanksgiving Parade Costs Set To Balloon For Content-Hungry NBC

Faraday Future plans to announce the date and detailed plan for the stock ticker symbol change in January 2025.
 &nbsp;

FFIE

Faraday Future Plans To Change its Stock Ticker Symbol From 'FFIE' To 'FFAI' In Early 2025

Agora Q3 EPADS $(0.26) Down From $(0.23) YoY, Sales $31.6M Down From $35.0M YoY

Offerings

State Street Plans Issuance Of $2.25B Of Senior Debt By Its Principal Banking Subsidiary, State Street Bank And Trust Company

IPOs

CGTL

Creative Global Technology Plans Pricing Of Its IPO Of 1.25M Ordinary Shares At $4.00 Per Share For Total Gross Proceeds Of $5M; To Commence Trading On November 26, Under The Ticker Symbol 'CGTL'

Eastman Kodak Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) shares closed Monday&#8217;s session up more than 18% after the company announced plans to terminate its U.S. pension program. Here&#8217;s <a href="https://www.benzinga.com/quote/KODK/news">what you need to know.</a>
What To Know: In a new regulatory filing, Kodak said the Kodak Retirement Income Plan Trust entered into a purchase and sale agreement with Mastercard Foundation in which Mastercard will purchase certain private equity ownership interests and other illiquid assets. 
Kodak will sell the illiquid assets with a value of $764.4 million for a purchase price of $550.6 million in cash. Additional buyers will acquire $87.3 million in assets.
According to <a href="https://www.wsj.com/articles/kodak-prepares-to-terminate-u-s-pension-book-gain-of-more-than-500-million-d0cfb621?mod=lead_feature_below_a_pos3">The Wall Street Journal</a>, Kodak&#8217;s pension plan is overfunded, with $3.5 billion in assets and $2.3 billion in liabilities. The termination process will involve selling illiquid assets, settling liabilities and replacing the plan with a new retirement program. 
The termination is expected to result in a cash gain of $530 million to $585 million after taxes. Kodak plans to use these proceeds to reduce its $460 million in long-term debt, which includes a 12.5% term loan. Under its credit agreement, the company must reduce its debt balance to $200 million with proceeds of this size.
This move is aimed at improving Kodak's financial health, reducing interest expenses and investing in core business areas like pharmaceutical chemicals. The process is expected to take over a year and plan participants will retain the full value of their benefits through annuities or lump-sum payouts.
Kodak closed its latest quarter with $214 million in cash after reporting a quarterly profit of $18 million.
KODK Price Action: Eastman Kodak shares closed Monday at $6.24 after gaining 18.4% during regular trading hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png" alt="" class="wp-image-664229" style="width:483px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK.png 1464w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/42174446/streaming-vinyl-propel-music-copyright-value-to-45-5-billion">Streaming, Vinyl Propel Music Copyright Value To $45.5 Billion</a></li>
</ul>
Photo: <a href="https://pixabay.com/users/jbooba-23039065/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7452562">Gregor Mima</a> from Pixabay.

KODK

Kodak Stock Is Trading At 52-Week Highs: What's Going On?

Tim Draper, a prominent venture capitalist and cryptocurrency enthusiast, has made Bitcoin price predictions since 2014.
That year, Draper predicted Bitcoin to be $10,000 by the end of 2017. Despite skepticism, his forecast proved accurate, as Bitcoin hit $10,000 in November 2017 during its dramatic bull run.
In 2018, Draper forecast Bitcoin to reach $250,000 by the end of 2022. This bold prediction was not fully realized, though Bitcoin did reach an all-time high of approximately $69,000 in November 2021.
When Bitcoin failed to hit the target price in 2018, Draper extended the timeline to mid-2023. The futurist and investor based this target price on mass adoption, particularly by women and retail investors.
Draper said in an interview with Benzinga: "My first prediction was in 2014 when Bitcoin was at $180. I said that it would be $10,000 in three years. Sure enough, by the end of 2017, Bitcoin hit $10,000. Since then, I have not been as prescient. I thought Bitcoin would hit $250,000 by 2022! I think I am going to be three years off.&#8221; Draper added: &#8220;I think we can chalk those three years up to a weak government that regulated rather than encouraged new technologies. Our new government is more encouraging."
Since the U.S. presidential election in November, the crypto world has been celebrating with a decidedly more bullish outlook. Though many tokens have seen significant gains, including Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Bitcoin has taken center stage, reaching a record high of $99,000 on Nov. 21, the second all-time high of the month.
Benzinga asked Draper what his prediction was for Bitcoin with the end of 2024 rapidly approaching and he responded: "This is just the beginning! If you are asking about price prediction, I would say about Bitcoin will reach about $120,000 by end of year."
Benzinga asked Draper what drives his future forecasts for Bitcoin, he pointed to the superiority of the cryptocurrency over traditional fiat and long-term trends in usage.
"It is a long-term trend. Bitcoin is just better technology than using banks and governments as the trusted third party. It is transparent, global, open, keeps perfect records, etcetera. It will make the world wealthier. When retailers (for currency) and governments (for taxes) realize that Bitcoin will save them money on each transaction, then there will be a great incentive for everyone to use Bitcoin."
When asked for his prognostication for 2025, Draper said he is holding out for the $250,000 level and cited the proposed U.S. Bitcoin reserve as a contributing factor.
"Assuming a standard supply and demand curve, if there is a big buyer like that, the price will continue to rise. I think 2025 is the year Bitcoin will finally hit my mark of $250,000," Draper noted.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">Bitcoin ETFs Registered Record $3.12 Billion Net Inflows Last Week</a>
<h1 class="wp-block-heading">MicroStrategy Leads the Bitcoin Charge</h1>
Michael Saylor, co-founder of MicroStrategy, <a href="https://x.com/saylor/status/1861033309934862601">tweeted today</a><a href="https://x.com/saylor/status/1861033309934862601" target="_blank" rel="noopener"> </a>that the company acquired $5.4 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), the single biggest purchase of the world's leading decentralized digital currency.
In the tweet, Saylor stated, "MicroStrategy has acquired 55,500 BTC for ~$5.4 billion at ~$97,862 per #bitcoin and has achieved BTC Yield of 35.2% QTD and 59.3% YTD. As of 11/24/2024, we hodl 386,700 $BTC acquired for ~$21.9 billion at ~$56,761 per bitcoin. $MSTR"
This is after the news that the company is making $500 million a day with its Bitcoin holdings, which Saylor said have appreciated by $5.4 billion over the past two weeks. Saylor predicted Bitcoin could reach $13 million by 2045, which would elevate its market cap to $250 trillion. 
<h1 class="wp-block-heading">Optimism Among Web3 Leaders</h1>
Nathan Berkley, CEO of Muhdo Health Limited, a health technology company specializing in DNA and epigenetic testing which incorporates cryptocurrency into its operations, has a bullish outlook on Bitcoin and independently concurs with Draper's forecast.
"I think we could see Bitcoin hit $120,000. With U.S. sentiment being positive to this market now, and understanding Web3 can have real impact, it's a great time to be in the space," Berkley noted.
Lisa Loud, executive director of Secret Network Foundation, a blockchain platform designed to enable privacy-preserving decentralized applications, said: "The Bitcoin of today is not the Bitcoin of 2020: we have a broader finance interest, politics, and uncertain regulatory changes. A conservative estimate would say it will end in the range of $92,000-115,000, but if we get a large opt-in from mainstream, we could blow this estimate out of the water."
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42173367/shiba-inu-burn-rate-soars-487-in-a-day-what-is-going-on"> • Shiba Inu Burn Rate Soars 487% In A Day: What Is Going On?</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

Trading Ideas

$BTC

$ETH

$SOL

$USDT

$XRP

EXCLUSIVE: Tim Draper Predicts Bitcoin To Reach $120K By End Of 2024, $250K In 2025

The Q4 earnings report for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBD

Earnings Summary: Blue Bird Q4

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.38 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Enanta Pharma Earnings Analysis: Q4 Recap

The Q4 earnings report for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) was released on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.11 in the last quarter, resulting in a 6.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENT

Central Garden & Pet: Q4 Earnings Insights

Leslie&#8217;s Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42174678/leslies-inc-announces-fourth-quarter-fiscal-2024-financial-results-provides-first-quarter-fiscal-2">details from the report. </a>
The Details: Leslie&#8217;s reported quarterly earnings of two cents per share which missed the analyst consensus estimate of 11 cents. Quarterly revenue came in at $397.9 million which missed the analyst consensus estimate of $405.19 million and is a decrease from sales of $432.37 million from the same period last year.
For the fiscal year 2024: 
<ul>
<li>Comparable sales decreased 8.8%. Non-comparable sales including acquisitions and new stores contributed $7.9 million for the year.</li>
<li>Gross profit decreased 13% to $476.8 million compared to $548.2 million in the prior year.</li>
<li>Gross margin decreased to 35.8% from 37.8% in the prior year period. </li>
<li>Operating income was $57.1 million compared to $102.2 million in the prior year.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;Our fourth quarter results were in line with our revised expectations on the top-line, and we saw strong performance in our Pro segment with some continued softness in store traffic and larger-ticket and discretionary categories. Profitability was affected by deleverage from the sales decline and a one-time contract item, though we have remained disciplined on SG&amp;A expenses,&#8221; said Jason McDonell, CEO of Leslie&#8217;s. 
Outlook: Leslie&#8217;s expects first-quarter sales of between $169 million and $176 million and gross profit of $45 million to $48 million. 
LESL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Leslie's shares are down 18.80% after-hours at $2.85 after gaining 10% during Monday&#8217;s regular trading session.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Oleg Gamulinskii from Pixabay

LESL

Leslie's Stock Drops After Q4 Results: Here's Why

SPIR

Spire Global Says Selected By LatConnect60 To Provide Global Navigation Satellite System Reflectometry Data And Soil Moisture Insights

The Company previously disclosed the retirement of E. Thomas Allen, Jr., the current Senior Executive Vice President and Chief Operating Officer of the Company and the Bank, effective as of January 31, 2025.

Management

CLBK

Columbia Financial Names Matthew Smith As Senior Executive Vice President And COO Of Company And The Bank Effective As Of November 25, 2024

Press Releases

Aluf Holdings Inc. Announces Exciting Developments in Biotech and Biometrics

Aluf Holdings Inc. Announces Retirement of Chairman, Donald C. Bennett

Aluf Holdings, Inc. Welcomes Dr. Matthew Leftwich CTO and COO to the Board and Announces Strategic Acquisition of Nanomatronix, LLC

Update from Aluf Holdings Inc. on Forthcoming Acquisition of Nanomatronix, LLC

AHIX

Aluf Hldgs

Aluf Holdings

Comments

Aluf Hldgs

Aluf Hldgs (AHIX) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO